By Professor Janaki Amin

Journal articles

Winston A; McAllister J; Amin J; Cooper DA; Carr AD, 2005, 'The use of a triple nucleoside-nucleotide-regimen for occupational HIV post-exposure prophylaxis', HIV Medicine, 6, pp. 191 - 197

Moyle G; Sawyer W; Law M; Amin J; Hill A, 2004, 'Changes in Hematologic Parameters and Efficacy of Thymidine Analogue - Based, Highly Active Antiretroviral Therapy: A Meta-Analysis of Six Prospective, Randomized, Comparative Studies', Clinical Therapeutics, 26, pp. 92 - 97, http://dx.doi.org/10.1016/S0149-2918(04)90009-4

Jauncey ME; Micallef JM; Gilmour S; Amin J; White PA; Rawlinson WD; Kaldor JM; Van Beek IA; Dore GJ, 2004, 'Clearance of hepatitis C virus after newly acquired infection ininjection drug users', Journal of Infectious Diseases, 190, pp. 1270 - 1274

Hallinan R; Amin J; Dore GJ, 2004, 'Hepatitis C virus incidence among injecting drug users on opioid replacement therapy', Australian and New Zealand Journal of Public Health, 28, pp. 576 - 578

Amin J; Kaye M; Skidmore S; Pillay D; Cooper DA; Dore GJ, 2004, 'HIV and hepatitis C coinfection within the CAESAR study', HIV Medicine, 5, pp. 174 - 179

Martin A; Smith DE; Carr AD; Ringland C; Amin J; Emery S; Hoy JF; Workman C; Doong N; Freund J; Cooper DA, 2004, 'Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study', AIDS, 18, pp. 1029 - 1036, http://www.medscape.com/viewarticle/474870

Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA, 2003, 'Combined Analysis of Two-Year Follow-Up from Two Open-Label Randomized Trials Comparing Efficacy of Three Nucleoside Reverse Transcriptase Inhibitor Backbones for Previously Untreated HIV-1 Infection: OzCombo 1 and 2', HIV Research & Clinical Practice, 4, pp. 252 - 261, http://dx.doi.org/10.1310/hct.2003.4.4.004

Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA; Kotsiou G; Norrito L; Dwyer D; Packham D; Fordham M; Garsia R; Baker D; Doong N; Quan D; Beveridge A; Genn W; Quin J; Mulholland J; Sowden D; Rawlinsen M; Rebic D; Street A; De Graaf B; Roney J; Bryant M; McCormack C; Hoy J; Shaw D; Ferguson W; Waddell R; Papanaoum K; French M; Mallal S; Scull N; Todhunter L; Jacobs S; James R; Foreman E; Chuah J; Watson A; Bowden F; Little B; Willington C; Habel P; Mills G; Morgan J; Thomas M; Porteous F; Franklin R; Reid M; Munro R; Sharkey T; Hudson J; Groves J; Blunt J; Clezy K; Lee W; Smith D; Cunningham P; Wood H, 2003, 'Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: Ozcombo 1 and 2', HIV Clinical Trials, 4, pp. 252 - 261, http://dx.doi.org/10.1310/K2U9-QC2V-1Y3V-5DYF

Micallef JM; Jauncey M; Amin J; Rawlinson W; Gilmour S; van Beek I; Kaldor JM; White PA; Dore GJ, 2003, '229 Hepatitis C virus reinfection within a cohort of injecting drug users', Hepatology, 38, pp. 266, http://dx.doi.org/10.1016/s0270-9139(03)80272-0

Mikhailof N; Carr A; Amin J; Cooper DA, 2002, 'Insulin resistance and HIV-related lipoatrophy [1] (multiple letters)', Journal of the American Medical Association, 288, pp. 1716, http://dx.doi.org/10.1001/jama.288.14.1716

French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D; investigators* OBOO2, 2002, 'Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study', HIV Research & Clinical Practice, 3, pp. 177 - 185, http://dx.doi.org/10.1310/hct.2002.3.3.001

Miller J; Brown DA; Amin J; Kent-Hughes J; Law MG; Cooper DA; Carr AD, 2002, 'A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia', AIDS, 16, pp. 2195 - 2200

Carr AD; Workman C; Smith DE; Hoy JF; Hudson J; Doong N; Martin A; Amin J; Freund J; Law MG; Cooper DA, 2002, 'Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy', JAMA - Journal of the American Medical Association, 288, pp. 207 - 215

Carr AD; Workman C; Smith DE; Hoy JF; Doong N; Amin J; Law MG; Cooper DA, 2002, 'For the MITOX investigators: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial', Journal of the American Medical Association, 288, pp. 207 - 215

Carr AD; Amin J; Cooper DA, 2002, 'Insulin resistance and HIV-related lipoatrophy', Journal of the American Medical Association, 288, pp. 1716

French MA; Amin J; Roth N; Law MG; Emery S; Drummond F, 2002, 'Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: The OzCombo 2 Study', HIV Clinical Trials, 3, pp. 177 - 185

Amin J; Gilbert GL; escott R; heath T; Burgess MA, 2001, 'Hepatitis A epidemiology in Australia: national seroprevalence and notifications', Medical Journal of Australia, 174, pp. 338 - 341

Amin J; Gidding H; Hull B; Torvaldsen S; Tucker A; Turnbull F; Burgess M, 2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998', Communicable Diseases Intelligence, 24, pp. vii, http://dx.doi.org/10.33321/cdi.2000.24.21

Gidding HF; Amin J; McIntyre PB, 2000, 'Notifications of vaccine preventable diseases in Australia. Quarterly report (January-March 2000).', Communicable Diseases Intelligence, 24, pp. 239 - 241

McIntyre P; Amin J; Gidding H; Hull B; Torvaldsen S; Tucker A; Turnbull F; Burgess M, 2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998.', Communicable Diseases Intelligence, 24, pp. 276 - 277

McIntyre P; Amin J; Gidding H; Hull B; Torvaldsen S; Tucker A; Turnbull F; Burgess M, 2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998.', Communicable Diseases Intelligence, Suppl

Amin J; McIntyre P; Gidding H; Turnbull F; Burgess M, 2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998', Communicable Diseases Intelligence Quarterly Report

Thomson J; Lin M; Halliday L; Preston G; McIntyre P; Gidding H; Amin J; Roberts L; Higgins K; Brooke F; Milton A; O'Brien E; Witteveen D; Crerar S, 1999, 'Australia's notifiable diseases status, 1998. Annual report of the National Notifiable Diseases Surveillance System.', Communicable Diseases Intelligence, 23, pp. 277 - 305

Heath T; Amin J; Morrell SL, 1999, 'Hepatitis A in Australia in the 1990s: future directions in surveillance and control', Communicable Diseases Intelligence, 23, pp. 113 - 120

Amin J; Wong M, 1999, 'Measles-mumps-rubella immunisation, autism and inflammatory bowel disease: update', Communicable Diseases Intelligence Quarterly Report

Amin J; Hueston L; Dwyer DE; Capon A, 1998, 'Ross River virus infection in the north-west outskirts of the Sydney basin', Communicable Diseases Intelligence Quarterly Report, 22, pp. 101 - 102

Amin J; McIntyre PB; Heath TC, 1998, 'Measles vaccine, inflammatory bowel disease and pervasive developmental disorder: is there cause for concern?', Communicable Diseases Intelligence, 22, pp. 58 - 59

Back to profile page